Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning.
Zaretsky Y, Rifkind J, Lockwood G, Tsang R, Kiss T, Hasegawa W, Fyles G, Tejpar I, Loach D, Minden M, Messner H, Lipton JH. Zaretsky Y, et al. Among authors: loach d. Bone Marrow Transplant. 2007 Sep;40(5):423-30. doi: 10.1038/sj.bmt.1705755. Epub 2007 Jul 2. Bone Marrow Transplant. 2007. PMID: 17603516
Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission.
Michelis FV, Atenafu EG, Gupta V, Kim DD, Kuruvilla J, Lipton JH, Loach D, Seftel MD, Uhm J, Alam N, Lambie A, McGillis L, Messner HA. Michelis FV, et al. Among authors: loach d. Bone Marrow Transplant. 2015 Jul;50(7):907-13. doi: 10.1038/bmt.2015.59. Epub 2015 Mar 30. Bone Marrow Transplant. 2015. PMID: 25822226
Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.
Michelis FV, Messner HA, Atenafu EG, Kim DD, Kuruvilla J, Lipton JH, Uhm J, Loach D, Gupta V. Michelis FV, et al. Among authors: loach d. Biol Blood Marrow Transplant. 2014 Apr;20(4):474-9. doi: 10.1016/j.bbmt.2013.12.560. Epub 2013 Dec 15. Biol Blood Marrow Transplant. 2014. PMID: 24345422 Free article.
Long-Term Incidence of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience.
Michelis FV, Kotchetkov R, Grunwald RM, Azeem A, Atenafu EG, Lipton JH, Loach D, Gupta V, Kuruvilla J, Kim DD, Viswabandya A, Deotare U, Messner HA. Michelis FV, et al. Among authors: loach d. Biol Blood Marrow Transplant. 2017 Jun;23(6):945-951. doi: 10.1016/j.bbmt.2017.02.015. Epub 2017 Feb 27. Biol Blood Marrow Transplant. 2017. PMID: 28254442 Free article.
Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation.
Mayo S, Messner HA, Rourke SB, Howell D, Victor JC, Kuruvilla J, Lipton JH, Gupta V, Kim DD, Piescic C, Breen D, Lambie A, Loach D, Michelis FV, Alam N, Uhm J, McGillis L, Metcalfe K. Mayo S, et al. Among authors: loach d. Bone Marrow Transplant. 2016 Jun;51(6):841-7. doi: 10.1038/bmt.2016.2. Epub 2016 Feb 29. Bone Marrow Transplant. 2016. PMID: 26926230
Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD.
Salas MQ, Prem S, Atenafu EG, Datt Law A, Lam W, Al-Shaibani Z, Loach D, Kim DDH, Michelis FV, Lipton JH, Kumar R, Mattsson J, Viswabandya A. Salas MQ, et al. Among authors: loach d. Bone Marrow Transplant. 2020 Sep;55(9):1773-1783. doi: 10.1038/s41409-020-0813-9. Epub 2020 Feb 5. Bone Marrow Transplant. 2020. PMID: 32024990
43 results